EMBC250117C17500
- 0.00
- 0.000.00%
Embecta Newsroom
Top SA Quant-rated Medical Devices Stocks as Technicals Look Strong
4 MedTech Stocks Poised to Thrive Under Second Trump Presidency
Aehr Test Systems Posts Weak Results, Joins Trump Media & Technology Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Embecta Management to Meet With BTIG
The Zacks Analyst Blog Highlights Doximity, BrightSpring Health Services and Embecta
3 Stocks Trading Near 52-Week High With Room to Rise Further
Zacks.com Featured Highlights Include The Gap, Embecta, Blue Bird and ZIM Integrated Shipping Services
Embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
Embecta | 10-K: FY2024 Annual Report
BTIG Maintains Embecta(EMBC.US) With Buy Rating, Maintains Target Price $26
BTIG Upgrades Embecta Corporation (EMBC) to a Buy
Embecta To Go Ex-Dividend On December 6th, 2024 With 0.15 USD Dividend Per Share
Embecta Corp Appoints Anthony Roth as VP and CAO
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley Upgrades Embecta to Equalweight, Price Target Is $20
Embecta Upgraded to Equal Weight From Underweight at Morgan Stanley
Is It Time To Consider Buying Embecta Corp. (NASDAQ:EMBC)?
This Dick's Sporting Goods Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Embecta Price Target Raised to $20 From $17 at BofA